Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

Jones, RH, Carucci, M, Casbard, AC et al. (10 more authors) (2019) Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial. In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .

Metadata

Authors/Creators:
  • Jones, RH
  • Carucci, M
  • Casbard, AC
  • Butler, R
  • Alchami, F
  • Bale, CJ
  • Bezecny, P
  • Joffe, J
  • Moon, S
  • Twelves, C
  • Venkitaraman, R
  • Waters, S
  • Howell, SJ
Dates:
  • Published (online): 26 May 2019
  • Published: 20 May 2019
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 17 Oct 2019 09:19
Last Modified: 23 Oct 2019 08:02
Status: Published
Publisher: American Society of Clinical Oncology
Identification Number: https://doi.org/10.1200/JCO.2019.37.15_suppl.1005
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)